Net Income (Loss) Attributable to Parent in USD of Verrica Pharmaceuticals Inc. from Q1 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Verrica Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2017 to Q3 2025.
  • Verrica Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$274K, a 98.8% increase year-over-year.
  • Verrica Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$26M, a 69.4% increase year-over-year.
  • Verrica Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$76.6M, a 14.3% decline from 2023.
  • Verrica Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$67M, a 174% decline from 2022.
  • Verrica Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$24.5M, a 30.2% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Verrica Pharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$26M -$274K +$22.6M +98.8% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$48.6M $204K +$17.4M 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$66M -$9.74M +$10.6M +52.1% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$76.6M -$16.2M +$8.41M +34.2% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025
Q3 2024 -$85M -$22.9M +$1.94M +7.83% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$86.9M -$17.2M -$6.2M -56.4% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$80.7M -$20.3M -$13.7M -209% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$67M -$24.6M -$18.7M -315% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025
Q3 2023 -$48.3M -$24.8M -$24.9M -29982% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024
Q2 2023 -$23.4M -$11M -$822K -8.08% 01 Apr 2023 30 Jun 2023 10-Q 05 Nov 2024
Q1 2023 -$22.6M -$6.59M +$1.88M +22.2% 01 Jan 2023 31 Mar 2023 10-Q 05 Nov 2024
Q4 2022 -$24.5M -$5.93M +$3.61M +37.8% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024
Q3 2022 -$28.1M $83K +$12.9M 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$41M -$10.2M +$1.61M +13.6% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$42.6M -$8.47M -$7.53M -805% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$35.1M -$9.54M +$3.44M +26.5% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023
Q3 2021 -$38.5M -$12.8M -$2.34M -22.3% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$36.2M -$11.8M -$2.37M -25.1% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$33.8M -$936K +$8.89M +90.5% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$42.7M -$13M -$5.34M -69.9% 01 Oct 2020 31 Dec 2020 10-K 02 Mar 2022
Q3 2020 -$37.4M -$10.5M -$4.4M -72.2% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$33M -$9.41M -$2.41M -34.4% 01 Apr 2020 30 Jun 2020 10-Q 12 Nov 2021
Q1 2020 -$30.6M -$9.82M -$2.34M -31.3% 01 Jan 2020 31 Mar 2020 10-Q 12 Nov 2021
Q4 2019 -$28.2M -$7.64M -$59K -0.78% 01 Oct 2019 31 Dec 2019 10-K 13 Mar 2020
Q3 2019 -$28.1M -$6.09M -$184K -3.12% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$28M -$7M -$1.68M -31.7% 01 Apr 2019 30 Jun 2019 10-Q 09 Nov 2020
Q1 2019 -$26.3M -$7.48M -$5.63M -305% 01 Jan 2019 31 Mar 2019 10-Q 09 Nov 2020
Q4 2018 -$20.6M -$7.58M -$6.14M -428% 01 Oct 2018 31 Dec 2018 10-K 13 Mar 2020
Q3 2018 -$14.5M -$5.91M -$4.55M -335% 01 Jul 2018 30 Sep 2018 10-K 13 Mar 2020
Q2 2018 -$9.96M -$5.32M -$4.22M -386% 01 Apr 2018 30 Jun 2018 10-K 13 Mar 2020
Q1 2018 -$5.74M -$1.85M -$1.28M -224% 01 Jan 2018 31 Mar 2018 10-K 13 Mar 2020
Q4 2017 -$4.46M -$1.44M 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019
Q3 2017 -$1.36M 01 Jul 2017 30 Sep 2017 10-K 07 Mar 2019
Q2 2017 -$1.1M 01 Apr 2017 30 Jun 2017 10-K 07 Mar 2019
Q1 2017 -$570K 01 Jan 2017 31 Mar 2017 10-K 07 Mar 2019

Verrica Pharmaceuticals Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$76.6M -$9.58M -14.3% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025
2023 -$67M -$42.5M -174% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025
2022 -$24.5M +$10.6M +30.2% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024
2021 -$35.1M +$7.61M +17.8% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023
2020 -$42.7M -$14.5M -51.4% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2022
2019 -$28.2M -$7.56M -36.6% 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2021
2018 -$20.6M -$16.2M -363% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020
2017 -$4.46M 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.